No significant differences in sex, smoking status, proportion of the neurological symptoms, maximum size of BMs, number of patients with leptomeningeal metastasis or the proportion of patients with Lung‐mol GPA ≥3 were observed among these three EGFR‐TKI treatment groups. This evidence concerns the gene EGFR and leptomeningeal metastasis.